title: Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.
abstract: Although the mechanisms of resistance to methotrexate (MTX) are known in experimental tumors made resistant to this drug, little information is available regarding acquired resistance to MTX in patients. A competitive displacement assay using the fluorescent lysine analogue of MTX, N-(4-amino-4-deoxy-N10-methylpteroyl)-N epsilon-(4'-fluorescein-thiocarbamyl)-L-lysine (PT430), was developed as a sensitive method of detection of transport resistance to MTX in cell lines, as well as in blast cells from patients with leukemia. Rapid uptake of PT430 at high concentrations (20 mumol/L) in leukemic blasts resulted in achievement of steady-state levels within 2 hours. Subsequent incubation with the folate antagonists, MTX and trimetrexate (TMTX), which differ in the mode of carrier transport, produced characteristic patterns of PT430 displacement. Flow cytometric analysis of the mean fluorescence intensity in the human CCRF-CEM T-cell lymphoblastic leukemia cell line and its MTX-resistant subline clearly identified the presence of transport deficiency in the resistant subline. Analysis of blasts from 17 patients with leukemia, nine with no prior chemotherapy and eight previously treated with chemotherapy, found evidence of MTX transport resistance in two of the four patients who were treated with MTX and considered to be clinically resistant to the drug. The finding that blast cells of some patients with leukemia considered clinically resistant to MTX is due to decreased MTX transport has important implications for clinical use of this drug and for new drug development.
authors.affiliation: Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: T
authors.initials: T
authors.lastname: Trippett
authors.forename: S
authors.initials: S
authors.lastname: Schlemmer
authors.forename: Y
authors.initials: Y
authors.lastname: Elisseyeff
authors.forename: E
authors.initials: E
authors.lastname: Goker
authors.forename: M
authors.initials: M
authors.lastname: Wachter
authors.forename: P
authors.initials: P
authors.lastname: Steinherz
authors.forename: C
authors.initials: C
authors.lastname: Tan
authors.forename: E
authors.initials: E
authors.lastname: Berman
authors.forename: J E
authors.initials: JE
authors.lastname: Wright
authors.forename: A
authors.initials: A
authors.lastname: Rosowsky
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001692:Biological Transport; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D011099:Polyglutamic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D016597:Trimetrexate / Q000493:pharmacokinetics; D014407:Tumor Cells, Cultured
chemical_list: D011099:Polyglutamic Acid; C014085:methotrexate polyglutamate; D016597:Trimetrexate; D008727:Methotrexate